Thymogen (Glu-Trp)
Thymogen is a peptide of just two amino acids, glutamic acid and tryptophan. It was identified in the search for the active part of the thymus extract Thymalin and has been a registered immune drug in Russia since 1990. It is not approved in the US.
- Legal lane: registered in Russia. Not FDA-approved.
- Evidence grade: C. Decades of clinical use in one country; little that meets modern trial standards.
- Form: injection and nasal spray in Russia
- What it is: the dipeptide Glu-Trp
What it is
Researchers looking for the active components of Thymalin arrived at the dipeptide Glu-Trp, which was registered as the drug Thymogen in 1990. A review of Russian peptide medicines lists it among the country's original registered peptide drugs, as an immune stimulant.
What the evidence shows
The clinical record is Russian and comes largely from the group that developed it. Their own reviews describe use in infections and in older patients.
A Russian drug handbook cited by St. Petersburg journalists lists Thymogen, like Thymalin, as having no evidence-based effectiveness. We found no large blinded trial in the sources we reviewed.
Legal status
- A registered drug in Russia.
- Not approved by the FDA.
- Not eligible for pharmacy compounding in the US, according to the research summary we read, and not one of the six peptides in the October 2026 policy.
Reported dosing
We do not publish a protocol for this compound.
The Russian product has its own label, which we have not been able to check directly. Figures on seller sites are not a source.
Safety
- A published chemistry review describes it as free of allergic and other side reactions. That is the developers' literature, not an independent safety review.
- Products sold abroad under this name are not the registered Russian product and have no verified contents.
Common questions
What is Thymogen?
A two-amino-acid peptide, Glu-Trp, registered as an immune drug in Russia.
Is Thymogen FDA-approved?
No.
How is Thymogen related to Thymalin?
It was identified as an active component of the Thymalin thymus extract and then made synthetically.
Ask an AI about this page
Opens the assistant with a question about this page already typed in. You can edit it before sending.
Ask ChatGPTAsk ClaudeAsk Perplexity
These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.
Sources
- Molecules, 2021: history of Thymalin (1982) and Thymogen (1990) registration
- Review of peptide drugs registered in the Russian Federation
- Paper (St. Petersburg), 2024: Khavinson's drugs and their critics in evidence-based medicine
- Khavinson, Kuznik and Ryzhak, 2014: the developers' own review of clinical use
- The Peptide Column: bioregulator research summary and legal status